Alan Tan
@alantanmd
Followers
2K
Following
2K
Statuses
3K
Associate Professor, Genitourinary Oncology researcher, bladder, RCC, Vanderbilt Ingram Cancer Center, GU Executive Officer @ALLIANCE_org NCTN
Nashville, TN
Joined June 2009
Thanks @CureMelanoma for the opportunity to discuss ctDNA in #melanoma, also thanks to my son Auguste for the #cameo appearance!
1
0
33
RT @nataliagandur: 🌟🧬 ctDNA: A game-changer in kidney cancer? 🔬🌟 @OncoAlert 📢 New study published! 👨⚕️ Author: @alantanmd 📄 Title: Explori…
0
12
0
RT @brian_rini: Listen to our #ASCOGU25 preview podcast on the bladder topics below plus prostate and RCC! Individual podcasts on the most…
0
13
0
RT @UrologyTimes: "The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance…
0
1
0
RT @VivekSubbiah: 📍Another tumor agnostic drug 👉🏼 #PrecisionMedicine for the 🏆👉🏼Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer |…
0
16
0
RT @tompowles1: Bladder cancer highlights #ASCOGU25 1) outcomes of pCR patients for gem/cis/durvalumab (NIAGARA) 2) neoadjuvant gem/cis/dur…
0
27
0
RT @ALLIANCE_org: New Trial Alert! .@BradMcG04 @DanaFarber leads @ALLIANCE_org A032201 (STRIKE) to compare the effect of adding tivozanib t…
0
10
0
@BradMcG04 @ALLIANCE_org @theNCI @Daniel_J_George @DrRosenbergMSK @MattGalsky @DrChoueiri @bergsa83 @DrRanaMcKay @DanaFarber_GU @kidneycan @KidneyCancer It’s time to #STRIKEout #RCC ⚾️ > 🎳
1
0
4
RT @BradMcG04: STRIKE activated; download docs today! @ALLIANCE_org @theNCI Can we prevent more recurrences with addition of 6 months of…
0
16
0
RT @DrDanielHeng: Treatment free survival is becoming an important endpoint when looking at different #mRCC treatments. VEGF alone had sh…
0
50
0
RT @ArndtVogel: Encorafenib + cetuximab + CTx in BRAF V600E-mutant CRC #ASCOGI25 🔎BREAKWATER 👉ORR 60 vs 40.0%, durable responses in BRAF V6…
0
44
0
RT @ArndtVogel: Nivolumab/ipilimumab versus nivolumab in MSI mCRC (CheckMate 8HW): a randomised, open-label, phase 3 trial 👇Get the full pa…
0
56
0
RT @CathyEngMD: Phase II #ctDNA in node (-) #rectal #cancer in the NEO-RT study @jonathanloree @HKennecke #cancer #CancerResearch @ASCO #A…
0
13
0
RT @Erman_Akkus: 💊Pan-RAS inhibitor Daraxonrasib in 2L of pancreatic cancer #GI25 @ASCO ✅ORR KRAS G12X: 36%, RAS mt: 27% ➡️For compariso…
0
36
0
RT @CathyEngMD: Post hoc analysis of CALGB 80702 in stage III ctDNA (+), with improved DFS following celebrex x 3 yrs, DFS HR = 0.55 as p…
0
16
0
RT @PatrickHwuMD: #ScienceSaturday ❓ What is the "obesity paradox" in cancer #immunotherapy? ➡️ Although obesity increases the risk of #…
0
11
0
RT @OncLive: Hereditary causes of cancer, the gut microbiome, environmental exposures...We know about what factors we can avoid, but what o…
0
2
0
RT @DavidBenjaminMD: Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma? In @EurUrolOncol, we di…
0
14
0
RT @DavidBenjaminMD: Is it time to re-classify urachal cancer as a GI rather than a GU malignancy? In @Nature_NPJ Precision Oncology, we s…
0
18
0
RT @DrFelixGuerrero: 😁Very honored of being part of this paper about the “History of TAR-200” just published in @UrolOncol 🤓Take a look: ht…
0
19
0
RT @DrYukselUrun: Can mpMRI replace TURBT for faster treatment in MIBC? A randomized study shows that the mpMRI-first approach reduced the…
0
32
0